Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.60
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (6.452%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.60
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: iEnergizer to depart; Unbound for sale

Fri, 19th May 2023 10:15

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

iEnergizer PLC, up 24% at 67 pence, 12-month range 29.5p-526p. The Noida, India-based IT service management firm says its shares will stop trading on AIM on Wednesday. In April, it said it was seeking cancellation, stating that staying on the stock exchange was "unlikely to provide the company with significantly wider access to capital", adding that the cost and legal implications of maintaining its admission to trading on AIM were "disproportionate" to the benefits.

----------

Genedrive PLC, up 16% at 23.70p, 12-month range 8.00p-48.86p. The point-of-care molecular diagnostics firm says the UK National Institute for Health & Care Excellence recommends in draft guidance that CYP2C19 genotyping should be used before clopidogrel administration in managing ischemic stroke patients. "Screening patients to assess their clopidogrel resistance status allows for alternative treatments and better clinical outcomes," the company explains. The NICE Committee included the firm's CYP2C19 ID test in its review. Genedrive notes the test is still in development. Awaits the UKCA marking on the test prior to NICE's final report, currently scheduled for October.

----------

AIM - LOSERS

----------

Velocys PLC, down 28% at 2.41p, 12-month range 2.20p-7.30p. The sustainable fuels technology company says the books are covered at around GBP6 million for its placing and retail offer. The books remain open. The fundraise was announced after the market close on Thursday, with an issue price of 2.5p for each. The price is a 26% discount to Thursday's closing price of 3.4p. Velocys had voiced concerns over its ability to continue as a going concern. It aims to raise at least GBP32 million by the placing, retail offer, open offer, as well as a conditional issuance of convertible loan notes to Carbon Direct Capital and potential further issuances of convertible loan notes and/or new ordinary shares to investors other than Carbon Direct Capital.

----------

Unbound Group PLC, down 23% at 2.51p, 12-month range 2.51p-35.94p. The stock reaches a 12-month low as the firm launches a strategic review, including a formal sales process. Unbound is the parent company for a retail group selling a range of brands focused on the 55+ demographic, including Hotter Shoes. The review is to explore its strategic options, and could include a full sale of the company. Unbound warns a temporary working capital shortfall could arise in September and October this year. It continues to work with its advisers and banking partners to raise additional funds or refinance its current facilities.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
7 Oct 2019 11:59

NHS Ethics Approval Granted For Genedrive MT-RNR1 Screening Test Trial

NHS Ethics Approval Granted For Genedrive MT-RNR1 Screening Test Trial

Read more
3 Oct 2019 11:00

Genedrive Outlook Positive As Revenue Up And Loss Narrows In Full Year

Genedrive Outlook Positive As Revenue Up And Loss Narrows In Full Year

Read more
3 Oct 2019 10:41

Genedrive loss narrowed after double-digit revenue rise

(Sharecast News) - Genedrive on Thursday reported a narrowed annual loss as revenues jumped as its commercial relationship with the US department of defense (DoD) exceeded expectations.

Read more
9 Jul 2019 10:54

Genedrive Revenue To Suffer On Lower Uptake Of Hepatitis Test Kits

(Alliance News) - Shares in Genedrive PLC fell Tuesday after the company warned that it will miss market expectations for 2020 financial year revenue due to slower than expected uptake of the HCV

Read more
28 Mar 2019 10:36

Genedrive Interim Loss Narrows As It Continues Focus On Hepatitis

LONDON (Alliance News) - Genedrive PLC on Thursday reported a reduction in its interim loss, as it continues to progress its hepatitis testing product.For the six months to the end of 2018,

Read more
28 Mar 2019 07:59

Genedrive losses narrow despite increased R&D costs

(Sharecast News) - Molecular diagnostics company Genedrive saw revenues tick ahead slightly in the first half of its financial year but increased research and development costs kept the firm in the red.

Read more
15 Jan 2019 12:44

Genedrive Interim Revenue Rises On US And UK Government Contracts

LONDON (Alliance News) - Genedrive PLC said Tuesday it increased its first-half income and made "good progress" on two UK government funded projects.For the six months to the end

Read more
15 Jan 2019 10:17

Genedrive makes progress with HCV kit in first half

(Sharecast News) - Near-patient molecular diagnostics company Genedrive issued an unaudited update for the six months ended 31 December on Tuesday, reporting revenue of £1.5m, up from £1.3m year-on-year.

Read more
10 Dec 2018 16:23

BGF Investment Management Now Owns 12.8% Stake In Genedrive (ALLISS)

LONDON (Alliance News) - Genedrive PLC said Monday that BGF Investment Management Ltd now owns a 12.8% stake in the company.BGF's stake in the firm prior to Monday's deal, if any,

Read more
29 Nov 2018 13:56

Genedrive To Participate In Study For Use Of HCV Assay In Pharmacies

LONDON (Alliance News) - Genedrive PLC on Thursday said it will participate in an international multicentre trial to assess the impact of out-reach HCV diagnostics and therapy in a pharmacy versus

Read more
29 Nov 2018 11:49

Genedrive to participate in three-country HCV therapy study

(Sharecast News) - Near-patient molecular diagnostics company Genedrive announced on Thursday that it will participate in an international multicentre trial, designed to assess the impact of outreach HCV diagnostics and therapy in a pharmacy setting when compared conventional treatment pathways.

Read more
22 Aug 2018 11:17

Genedrive Appoints Chris Yates As Non-Executive Director

LONDON (Alliance News) - Diagnostics company Genedrive PLC said Wednesday it appointed Chris Yates as non-executive director with immediate effect.Yates has been Chief Executive Officer of

Read more
8 Aug 2018 12:05

Genedrive Partners With FIND To Evaluate Its Hepatitis C Virus Kit

LONDON (Alliance News) - Genedrive PLC said Wednesday it partnered with the Foundation for Innovation of New Diagnostics, or FIND, which will evaluate its hepatitis C virus kit.The kit is a

Read more
20 Jun 2018 09:57

Genedrive Given Grant For NHS Point-Of-Care Test Development

LONDON (Alliance News) - Genedrive PLC's said Wednesday it was awarded a multi-partner grant to develop a pharmacogenetic test to fight antibiotic-related hearing loss in newborn molecular was

Read more
14 May 2018 18:07

Genedrive To Sell Two Divisions For Up To GBP1.9 Million In Cash

LONDON (Alliance News) - Genedrive PLC said Monday it proposed the disposal of the its contract research and pharmacogenomics divisions for up to GBP1.9 million in cash to biotechnology company 2

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.